Sulpirid — Competitive Intelligence Brief

Sulpirid (SULPIRIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: High Risk QT Prolonging Agents. Area: Neuroscience.

discontinued High Risk QT Prolonging Agents Carbonic anhydrase 6 Neuroscience Small molecule

Target snapshot

Sulpirid (SULPIRIDE). Sulpiride works by blocking the action of carbonic anhydrase 6, an enzyme that helps regulate the balance of acid and base in the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sulpirid TARGET	SULPIRIDE		discontinued	High Risk QT Prolonging Agents	Carbonic anhydrase 6
Trisenox	ARSENIC TRIOXIDE	Cephalon	marketed	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2	2000-01-01
Sparcin	SPARFLOXACIN		marketed	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2	1996-01-01
Alimix	CISAPRIDE		marketed	High Risk QT Prolonging Agents	5-hydroxytryptamine receptor 2A	1993-01-01
Orlaam	LEVOMETHADYL ACETATE	Roxane	marketed	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2	1993-01-01
Org 5730	BEPRIDIL		marketed	High Risk QT Prolonging Agents	Voltage-dependent P/Q-type calcium channel subunit alpha-1A	1990-01-01
Hismanal	ASTEMIZOLE		marketed	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2	1988-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (High Risk QT Prolonging Agents class)

1. · 8 drugs in this class
2. Cephalon · 1 drug in this class
3. Pfizer · 1 drug in this class
4. Roxane · 1 drug in this class